A carregar...
Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women
BACKGROUND: The integrase inhibitor regimen [elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (TDF)] demonstrated superior efficacy when compared with a protease inhibitor regimen [ritonavir-boosted atazanavir (ATV + RTV) and FTC/TDF] in 575 treatment-naive women at week 48. We in...
Na minha lista:
| Publicado no: | J Acquir Immune Defic Syndr |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6425939/ https://ncbi.nlm.nih.gov/pubmed/29481486 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAI.0000000000001663 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|